News

MHLW (Japan) approval for Phesgo, the fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast and colorectal cancer

Read time: 1 mins

Published:27th Sep 2023

Chugai Pharmaceutical Co., Ltd. announced that it has obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for Phesgo combination for Subcutaneous Injection MA, IN [generic name: pertuzumab (genetical recombination), trastuzumab (genetical recombination) and vorhyaluronidase alfa (genetical recombination) ] (hereafter, Phesgo), antineoplastic agent / anti-HER2 humanized monoclonal antibody for the treatment of “HER2-positive breast cancer” and “Advanced or recurrent HER2-positive colorectal cancer that has progressed following cancer chemotherapy and is not amenable to curative resection.”

“We are pleased to have obtained approval in Japan for Phesgo, a fixed-dose combination for subcutaneous use containing the same anti-HER2 agents of Perjeta and Herceptin, the standard therapy for HER2-positive breast cancer. Reducing administration time is expected to improve convenience for patients and reduce the burden on healthcare system and professionals. We are preparing for the launch of this drug so that it can be used for treatment as soon as possible,” said Dr. Osamu Okuda, Chugai’s President and CEO.

This subcutaneous fixed-dose combination without preparation contains the same monoclonal antibodies as Perjeta and Herceptin, and also a vorhyaluronidase alfa (genetical recombination) combined in a single vial. It takes over eight minutes for a loading dose of Phesgo and over five minutes for the subsequent doses. By comparison, it takes 150 minutes for a sequential infusion of a loading dose of Perjeta and Herceptin using intravenous formulations (excluding follow-up observation), and 60-150* minutes for the subsequent maintenance dose infusions.

Condition: Breast Cancer HER2+

Type: drug

Learning Zone Homepage

Supportive care in oncology Learning Zone

Supportive care in oncology from a multidisciplinary team involves caring for patients with cancer, treatment adherence and adverse effect management.

Learning Zone

CDK4/6 inhibitors in breast cancer

Are you familiar with the clinical trial evidence that could help you to select the best cyclin dependent kinase 4/6 (CDK4/6) inhibitor for your metastatic breast cancer patient?

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

European Commission approval for Kalydeco to treat infants with cystic fibrosis ages 1 month and older.- Vertex.

Vertex Pharmaceuticals announced that the European Commission has granted approval for the label expansion of Kayydeco (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.

1 mins

Drug news

Novavax is prepared to deliver protein-based non-mRNA JN.1 COVID-19 vaccine in line with WHO recommendation this fall.

Novavax is Prepared to Deliver Protein-based Non-mRNA JN.1 COVID-19 Vaccine in Line with WHO Recommendation this Fall

1 min

Drug news

CHMP positive for Jeraygo (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.- Idorsia Ltd.

Idorsia Ltd announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), adopted a positive opinion for the use of Jeraygo (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.

1 min

See all news